Updated March 25th, 2024 at 16:03 IST

Novo Nordisk acquires Cardior Pharmaceuticals for up to $1.1 billion

The acquisition marks a strategic move for Novo Nordisk, aligning with its objective to broaden its portfolio to include treatments for cardiovascular diseases.

Reported by: Business Desk
Novo Nordisk Cardior Pharmaceuticals acquisition | Image:Republic
Advertisement

Denmark-based pharmaceutical giant Novo Nordisk announced on Monday its agreement to acquire Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion), aiming to bolster its cardiovascular pipeline and expand beyond its core focus on diabetes and weight-loss therapies.

The acquisition marks a strategic move for Novo Nordisk, aligning with its objective to broaden its portfolio to include treatments for cardiovascular diseases. In a statement, Novo Nordisk emphasized that integrating Cardior Pharmaceuticals into its operations will reinforce its pipeline of cardiovascular projects, complementing its existing programs across all phases of clinical development.

Advertisement

As part of the deal, Novo Nordisk will gain access to Cardior's lead compound CDR132L, currently undergoing phase 2 clinical development for the treatment of heart failure.

The transaction structure involves an upfront payment, with additional payments contingent upon the achievement of specified development and commercial milestones. Novo Nordisk intends to finance the acquisition using its financial reserves.

Advertisement

The acquisition reflects Novo Nordisk's commitment to advancing innovation in healthcare and addressing unmet medical needs in cardiovascular medicine.

(With Reuters inputs.)

Advertisement

Published March 25th, 2024 at 16:03 IST